



OnDose™ Analysis

PHYSICIAN

Test HCP MD
 Test Medical Center
 123 Main St
 Testville, TX 55555

SPECIMEN

Specimen Type: Plasma
 Draw Date: 05-JUN-2009
 Accession Date: 09-JUN-2009
 Report Date: 12-JUN-2009

PATIENT

Name: Last179, First179
 Date of Birth: 07-APR-1948
 Patient ID: HCP179
 Gender: Female
 Accession #: 70000182-BLD
 Requisition #: 70000182

Test Results

FOLFOX

Infusion Start Time

05-JUN-2009 02:00 PM

Draw Time

05-JUN-2009 04:00 PM

Infusion Duration

46 hours

Test Performed

OnDose (5-FU AUC)


Result

22 mg · h/L

Target Range

20- 24 mg · h/L

The assay consists of biochemical analysis that measures the concentration of 5-FU using a two-reagent immunoagglutination technique. The Area Under the Curve (AUC) is calculated from the measured concentration of 5-FU multiplied by the infusion duration. This result assumes the patient was at steady state when the sample was drawn, the sample was drawn peripherally (i.e. not drawn from a portacath) and that the sample was handled according to laboratory instructions. The basis for the quantitative target range **in colorectal cancer**, as noted on this report, is found in the following studies: Gamelin E et al, J. Clin Onc. 2008; 26: 2099-105, Ychou M et al, Cancer Chemother Pharmacol. 2003; 52: 282 - 290, Gamelin E et al, J. Clin Onc. 1998; 16: 1470-1478, Gamelin E et al, Cancer. 1996; 77:441-51.



Draw Date	24-APR-2009	08-MAY-2009	22-MAY-2009	05-JUN-2009
AUC (mg · h/L)	11	17	21	22
Dose (mg/m ²)	2,400	3,120	3,430	3,430

Please Contact Myriad Professional Support at 1-800-469-7423 to discuss any questions regarding this result.

Further information may be found in the technical specifications, which can be accessed at www.myriad.com or by contacting Myriad. This test was developed and its performance characteristics determined at Myriad Genetics Laboratories, Inc. This test may be considered investigational in some states and has not been reviewed or approved by the U.S. Food and Drug Administration. These test results should be evaluated in conjunction with the patient's clinical history and current therapeutic regimen. Myriad, the Myriad logo, OnDose and the OnDose logo are either trademarks or registered trademarks of Myriad Genetics, Inc., in the United States and other jurisdictions.



OnDose™ Analysis

PHYSICIAN

Test HCP MD
 Test Medical Center
 123 Main St
 Testville, TX 55555

SPECIMEN

Specimen Type: Plasma
 Draw Date: 05-JUN-2009
 Accession Date: 09-JUN-2009
 Report Date: 12-JUN-2009

PATIENT

Name: Last179, First179
 Date of Birth: 07-APR-1948
 Patient ID: HCP179
 Gender: Female
 Accession #: 70000182-BLD
 Requisition #: 70000182

Test Results

FOLFOX

<u>Infusion Start Time</u>	<u>Draw Time</u>	<u>Infusion Duration</u>
05-JUN-2009 02:00 PM	05-JUN-2009 04:00 PM	46 hours

<u>Test Performed</u>	<u>Result</u>	<u>Target Range</u>
OnDose (5-FU AUC)	22 mg · h/L	20- 24 mg · h/L

The assay consists of biochemical analysis that measures the concentration of 5-FU using a two-reagent immunoagglutination technique. The Area Under the Curve (AUC) is calculated from the measured concentration of 5-FU multiplied by the infusion duration. This result assumes the patient was at steady state when the sample was drawn, the sample was drawn peripherally (i.e. not drawn from a portacath) and that the sample was handled according to laboratory instructions. The basis for the quantitative target range in colorectal cancer, as noted on this report, is found in the following studies: Gamelin E et al, J. Clin Onc. 2008; 26: 2099-105, Ychou M et al, Cancer Chemother Pharmacol. 2003; 52: 282 - 290, Gamelin E et al, J. Clin Onc. 1998; 16: 1470-1478, Gamelin E et al, Cancer. 1996; 77:441-51.



Draw Date	24-APR-2009	08-MAY-2009	22-MAY-2009	05-JUN-2009
AUC (mg · h/L)	11	17	21	22
Dose (mg/m²)	2,400	3,120	3,430	3,430

Please Contact Myriad Professional Support at 1-800-469-7423 to discuss any questions regarding this result.

Further information may be found in the technical specifications, which can be accessed at www.myriad.com or by contacting Myriad. This test was developed and its performance characteristics determined at Myriad Genetics Laboratories, Inc. This test may be considered investigational in some states and has not been reviewed or approved by the U.S. Food and Drug Administration. These test results should be evaluated in conjunction with the patient's clinical history and current therapeutic regimen. Myriad, the Myriad logo, OnDose and the OnDose logo are either trademarks or registered trademarks of Myriad Genetics, Inc., in the United States and other jurisdictions.